Qualcomm Life said it has been selected by pharmaceutical major Novartis as a digital health collaborator for its Trials of The Future program.
Qualcomm Life’s 2net Platform will serve as a connectivity platform for collecting and aggregating medical device data during clinical trials to improve the convenience and speed of capturing study participant data and test results.
You can watch and subscribe: Latest videos on telecoms
Qualcomm said the Trials of The Future program is designed to leverage health care technology to improve the experience of clinical trial participants and patients using Novartis products, and provide connectivity with future products marketed by Novartis.
Meanwhile, Qualcomm Life is also collaborating with Walgreens to power device connectivity with Walgreens mobile and web applications and its Balance Rewards for healthy choices program with medical device connectivity and care coordination capabilities.
Within the apps, Qualcomm Life’s 2net Platform will enable remote patient monitoring, transitional care support and chronic care management through seamless transmission of biometric data from patients’ connected medical devices.
Compatible Walgreens devices include a wrist-worn blood pressure cuff, a traditional blood pressure cuff and a blood glucose meter. The Walgreens applications and Qualcomm-enabled branded devices will be available to consumers in the first half of 2015.
editor@telecomlead.com
